Trump announces trade deal with EU following months of negotiations
Dennis Cho, Senior Vice President, Chief Legal Officer, and Corporate Secretary at Twist Bioscience Corp (NASDAQ:TWST), recently sold shares of the company’s stock valued at approximately $11,332. The transaction, dated March 6, involved the sale of 277 shares at a price of $40.913 each. The stock, which has shown significant volatility according to InvestingPro data, currently trades at $36.71, down about 15% year-to-date. The company maintains a FAIR overall financial health score of 2.45 out of 5.
According to the filing, these sales were made to cover tax withholding obligations related to the vesting of Restricted Stock Units and were not discretionary trades by Cho. Following this transaction, Cho holds 111,984 shares of Twist Bioscience. The company maintains strong liquidity with a current ratio of 4.96, operating with moderate debt levels. InvestingPro analysis suggests the stock is currently fairly valued, with additional insights available in the comprehensive Pro Research Report, one of 1,400+ detailed company analyses available to subscribers.
In other recent news, Twist Bioscience Corporation reported financial results for the first quarter of fiscal year 2025 that exceeded both consensus predictions and its own guidance. The company updated its full-year fiscal 2025 guidance, projecting total revenue growth of 19-21% year-over-year, an increase from the previous forecast of 17-20%. Gross margins are expected to be around 49% for the full year, with a slight increase anticipated in the fourth quarter. Analyst firms have reacted positively to these developments, with Scotiabank (TSX:BNS) raising the company’s price target to $62 and maintaining a Sector Outperform rating. Barclays (LON:BARC) also increased its price target to $58, citing growing momentum in Twist Bioscience’s Express portfolio and Next-Generation Sequencing tools. At its recent Annual Meeting of Stockholders, the company approved an increase in authorized common stock by an additional 100 million shares and amended its equity incentive plan. These amendments aim to provide more flexibility in compensating and incentivizing employees. The corporate changes reflect Twist Bioscience’s strategy to align employee interests with those of its shareholders.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.